TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
No significant safety or dose limiting toxicities reportedPK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results